BIIB · Plain-English company overview
A stock is a share of ownership in a company. Owning one means you own a small piece of that business.
In the company's own words, from Item 1 (Business) of its latest annual report (Form 10-K) filed with the SEC on 2026-02-06.
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.
Our marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.
Read the full 10-K on SEC.gov →
An earnings release is a company's quarterly report of how much money it made. Analysts predict these numbers ahead of time, and the actual results are compared against those predictions.
In the most recent quarter (2026-06-30), Biogen reported earnings of $3.6 per share. Analysts expected $3.0062 per share, so the company beat expectations.
Zelothorn provides plain-English summaries drawn from official SEC filings for educational purposes only. It is not financial advice and does not recommend buying or selling any security.